Physician profile
Charles Sadder
NPI 1730621814
$516.87
in general payments reported to CMS, 2019-2025
15 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $79.05 · 2022: $82.15 · 2023: $135 · 2024: $95.15 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $342 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $342.07 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $98.74 | 2024-2025 | Fanapt |
| Corium, LLC | $57.63 | 2023-2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $54.23 | 2022-2023 | Uzedy, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $53.39 | 2021-2023 | Trintellix |
| Sunovion Pharmaceuticals INC. | $42.47 | 2021-2022 | |
| Almatica Pharma LLC | $40.28 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Lundbeck LLC | $32.39 | 2022-2025 | Rexulti |
| Indivior INC. | $24.62 | 2025 | Sublocade |
| Ironshore Pharmaceuticals INC. | $22.32 | 2024 | |
| Tris Pharma INC | $19.63 | 2024 | Dyanavel Xr |
| Gilead Sciences, INC. | $17.20 | 2023 | |
| Supernus Pharmaceuticals, INC. | $14.54 | 2022 | |
| Merck Sharp & Dohme LLC | $14.37 | 2023 | Belsomra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.74 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Sadder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.